Spero Therapeutics, Inc. (SPRO) stock
SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 11/3046% below fair value
$0.87−0.03 (-3.03%)
Close on Nov 18, 2026Market cap $50.90MP/E 21.9Yield –
Spero Therapeutics free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Spero Therapeutics's free cash flow for the twelve months ending Dec 31, 2020 was -$86.03M. For fiscal 2020 it was -$86.03M. The highest annual figure on record is -$9.84M in fiscal 2015.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | -$86.03M | – |
| FY2019 | Dec 31, 2019 | -$50.33M | – |
| FY2018 | Dec 31, 2018 | -$42.06M | – |
| FY2017 | Dec 31, 2017 | -$39.14M | – |
| FY2016 | Dec 31, 2016 | -$29.79M | – |
| FY2015 | Dec 31, 2015 | -$9.84M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2021 | Sep 30, 2021 | -$4.95M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.40M | – |
| Q3 FY2020 | Sep 30, 2020 | -$21.32M | – |
| Q2 FY2020 | Jun 30, 2020 | -$24.91M | – |
| Q1 FY2020 | Mar 31, 2020 | -$23.41M | – |
| Q4 FY2019 | Dec 31, 2019 | -$17.50M | – |
| Q3 FY2019 | Sep 30, 2019 | -$9.68M | – |
| Q2 FY2019 | Jun 30, 2019 | -$12.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$11.01M | – |
| Q4 FY2018 | Dec 31, 2018 | -$15.92M | – |
| Q4 FY2016 | Dec 31, 2016 | -$9.47M | – |
See a number that looks wrong?